These findings underscore the central role of lipid metabolism in melanoma heterogeneity and suggest that therapeutic targeting of fatty acid synthase, CPT1A-mediated oxidation, or cholesterol pathways (e.g., statins) could be effective strategies. The gene discussed is CPT1A; the disease is melanoma.